Achillion
—ACH-1625
Arena, Vivus, and Orexigen—Weight Loss Drug Comparison
Avanir Pharmaceuticals
—Zenvia Part I, Part II, Part III, Market Share Estimate, STAR TRIAL MS subset Data Analysis
Biomoda
—CyPath Lung Cancer Test Part I, Part II, Part III
Cell Therapeutics
—Opaxio/Xyotax Part I, Part II, Part III
—Pixantrone Extend Trial
CombinatoRX
—Exalgo Approval Estimate, The FDA’s Reasons for possibly not approving the NDA (here)
Genta
—Genasense Part I, Part II, Part III, Part IV
Generex
–AE37
—Oral-Lyn RapidMist Part I, Part II, Part III
GenVec
—TN Ferade
HemispherX
—Ampligen Part I, Part II, Part III
Keryx
—Perifosine Part I, Part II, Part III
Raptor
—Cysteamine Part I, Part II, Part III
Sunesis
—Voreloxin Part I, Part II, Part III, Part IV
YM Biosciences
—Nimotuzumab Part I Part II, Part III, Part IV
Twitter
Thank you so much for your insightful analyses. I’m now hooked.
Besides YMI, I own Access, GenTec, CombinatoRx, Nephros, Perigrine, NexMed and Novadel. I’ve been investing for about 3 months and am attracted to pharmaceuticals. I also own Spng and Exph. As soon as one of the latter two takes off, I plan to put more into pharmaceuticals. I don’t have any questions at this point, but I am so impressed with you articles and can’t wait to read more. I hope you don’t mind that I think of you as a resource. Up to now I’ve done pretty well mostly by instinct..
Well, thank you again.
Richard Farina
I am anxiously waiting for part III on Opaxio.
Thank you for your work and the format in this bioscience area that I am reading as a review as well. You are trying to be very thorough, I appreciated that. Please keep it going.
What do you think would be the fair value for YMI? Thanks.
I am very impressed with your blog. Could you tell us about your back ground and how you arrive at this analysis?
Did you ever look at RPTPD?
Thanks.
I just recently found your website through a friend a few weeks ago. I think the amount of detail you put into your analysies are fantastic. I’m heavy on biomed stocks, and I follow a few of the companies you’ve mentioned, and that information that you’ve posted is better than anything else I’ve found online.
I know you are mainly in biomeds, but I’d really like your input on EDWY, eDoorways corp. This company could be the next Facebook, and could be very beneficial to your website as well. Please let me know what you think. Look forward to hearing from you soon.
Aaron
Good work! Thanks so much for your effort. I’m anxiously waiting on your further analysis on Generex’s Oralyn..
The GNBT part II and III reports have been delayed. Any time schedule to publish your new research?
I manage to find your GNBT Part II report is up. Excllent work.
Should HEB be approved, does all this legal stuff just “go away” or how does this effect the situation. No approval and lawsuit = company failure. given. but lawsuit + approval = ?
Thanks for the detailed info put in terms that I, a layman without a great science background, can understand.
hey just curious if you have followed SOMX at all
Do you have any analysis for GTHP (Guided Theraupatics)? formerly known as Spectra Rx.
When I click on your link
http://www.aweber.com/z/c/?jyczsy037hq5to2m6mpe9n0dqu3c7q5246
This is what I get
Not Found
Apologies, but we were unable to find what you were looking for. Perhaps searching will help.
Search for:
» Or go to the homepage
Could you please give us any info you may have on the Labopharm FDA approval , but share drop after approval?
Hi there, have you followed AP Pharma or have any opinion or information on their upcoming FDA date of 03/18? Thanks..
I have a q about a company for you to analyse if you ever get time the company is OPEXA and they are developing a drug for ms i took a position it the company at two dollars and it is tradeing at 2.60 are you familiar with this company and do you have any opinions. thanks so much.